Skip to main content
Full access
Letters
Published Online: 1 April 2012

Toxic Interaction Between Fluoxetine And Donepezil: A Case Of Cholinergic Toxidrome

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Donepezil is a reversible inhibitor of the enzyme acetylcholinesterase used to treat mild-to-moderate dementia. It is metabolized by CYP 450 isoenzymes 2D6 and 3A4. We present a patient who developed cholinergic toxicity from donepezil after starting fluoxetine.
Mr. K is a 65 yo male with schizoaffective disorder, bipolar type. He was admitted to an inpatient psychiatric unit due to increased agitation, fecal incontinence, and new behaviors of smearing feces and repeatedly placing his fingers in his rectum. His vitals were 129/56; 107, 20, 96.1. Physical exam was notable for excessive salivation, lacrimation, and fecal incontinence. He drooled excessively and periodically used a small towel and shoved deep into in his mouth. He made eye contact and nodded periodically in response to questions but was otherwise unable to meaningfully engage in interview. Complete blood count and chemistry panel were within normal limits.
The patient was restarted on all of his outpatient medications including fluoxetine 20mg daily and donepezil 10mg nightly. Records indicated that he had been on donepezil for the last 3 years and that fluoxetine was added 2 weeks prior to admission. Due to concern for a cholinergic toxidrome, donepezil and fluoxetine were discontinued. Within 48-hours the patient’s symptoms improved. He drooled less and no longer placed towels into his mouth. His diarrhea improved and ceased entirely which resulted in less preoccupation with his rectum. He became less agitated and was able to respond verbally to simple questions and able to communicate his needs to staff.

Discussion

The cholinergic toxidrome is well known by the mnemonic SLUDGE (salivation, lacrimation, urination, diarrhea, GI distress, and emesis). To our knowledge this is the first reported case in the literature of a drug-drug interaction between donepezil and fluoxetine. We are aware of two published cases reporting possible interaction between donepezil and paroxetine.1 This report cautions against the concomitant use of donepezil and other SSRIs that inhibit CYP450 2D6 including fluoxetine. It is well documented that fluoxetine is a potent inhibitor of CYP450 2D6 which can lead to elevated drug levels of medications metabolized by this system.2 It is highly probable that combining donepzil with fluoxetine led to elevated serum levels and adverse effects. According to the package insert, frequent side effects of donepezil include fecal incontinence, irritability and aggression; drooling is an infrequent side effect. The fact that Mr K’s symptoms resolved when the medications were discontinued, we surmise that symptoms of cholinergic toxicity were due to increased levels of donepezil after recent addition of fluoxetine to his medication regime. This information, coupled with the knowledge that elderly adults metabolize medications slowly and are often more sensitive to side effects than younger patients, leads us to caution against using fluoxetine in combination with donepezil.

References

1.
Carrier L: Donepezil and paroxetine: possible drug interaction. J Am Geriatr Soc 1999; 47:1037
2.
Otton SV, Wu D, Joffe RT, et al.: Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401–409

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E50
PubMed: 22772705

History

Published online: 1 April 2012
Published in print: Spring 2012

Authors

Affiliations

Katherine Marshall, M.D.
UC Davis Department of Psychiatry, Sacramento, CA
Kathy Fritz, Pharm.D.
UC Davis Department of Psychiatry, Sacramento, CA
Wayne Thom, M.D.
UC Davis Department of Psychiatry, Sacramento, CA
Glen L. Xiong, M.D.
UC Davis Department of Psychiatry, Sacramento, CA

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share